• / Free eNewsletters & Magazine
  • / My Account
Home>Oncodesign Launches Its New Website

Oncodesign Launches Its New Website

Oncodesign Launches Its New Website


Oncodesign Launches Its New Website

  • New communication policy attuned to Oncodesign’s biopharmaceutical positioning
  • Spotlight on the new service, partnership and licensing offerings for customers
  • More intuitive and clearer browsing structure for easier access to information

Regulatory News:

Oncodesign (Paris:ALONC) (ALONC – FR0011766229), a biopharmaceutical group specialized in precision medicine, announces the launch of its new website designed to reflect the Group’s latest developments.

The new website (www.oncodesign.com) aims to highlight Oncodesign’s biopharmaceutical positioning, the Group’s new service, partnership and licensing offerings for its customers, and its strategic and technological vision. Its goal is to provide relevant information, interactively and in a manner geared to Oncodesign’s markets.

The new website is designed to work on all the latest communication platforms (tablet, smartphone, PC, etc.) and caters to the needs of big pharma, biotechs and public research institutions, on whose behalf Oncodesign orients the research and development of new therapeutic and diagnostic tools. A new Investor area has also been created for its shareholders, plus a Careers section to help recruit the talent it needs to fulfil its goals.

This new website marks the start of a new communication policy, which aims to be more interactive and attuned to Oncodesign’s goals.

To see the new website, go to www.oncodesign.com

About ONCODESIGN: www.oncodesign.com

©2017 Morningstar Advisor. All right reserved.